Cargando…

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

PURPOSE: To examine whether age-related reference ranges for “normal” prostate-specific antigen (PSA) change (determined in men without prostate cancer) can be used to identify men at high risk of having prostate cancer. METHODS: Subjects were men aged 50–69 years with PSA < 10 ng/mL from the UK-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilbert, Rebecca, Tilling, Kate, Martin, Richard M., Lane, J. Athene, Davis, Michael, Hamdy, Freddie C., Neal, David E., Donovan, Jenny L., Metcalfe, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834577/ https://www.ncbi.nlm.nih.gov/pubmed/29453511 http://dx.doi.org/10.1007/s10552-018-1014-3

Ejemplares similares

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
por: Harrison, Sean, et al.
Publicado: (2020)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
por: Young, Grace J, et al.
Publicado: (2017)

Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study
por: Horwood, Jeremy P, et al.
Publicado: (2014)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
por: Walsh, Eleanor I., et al.
Publicado: (2016)

Do people who choose their treatment in a large randomised trial with parallel preference groups differ at baseline from those who agree to random treatment allocation? Results from the protect study
por: Mills, Nicola, et al.
Publicado: (2015)

The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals
por: Avery, Kerry NL, et al.
Publicado: (2014)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk
por: Lewis, Sarah J., et al.
Publicado: (2010)

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study
por: Gilbert, Rebecca, et al.
Publicado: (2014)

Evaluating best practice in informed consent discussions: a new method of evaluating information provision and patient understanding during trial recruitment consultations
por: Wade, Julia, et al.
Publicado: (2013)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial
por: Er, Vanessa, et al.
Publicado: (2017)

Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification
por: Hackshaw-McGeagh, Lucy E, et al.
Publicado: (2015)

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial
por: Lane, Athene J, et al.
Publicado: (2011)

Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in (11)C-Acetate PET/CTAC Scanning for Prostate Cancer Recurrence
por: Dusing, Reginald W., et al.
Publicado: (2014)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)
por: Merriel, Samuel William David, et al.
Publicado: (2017)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
por: Donovan, Jenny L., et al.
Publicado: (2018)

A model of the natural history of screen-detected prostate cancer
por: Metcalfe, C, et al.
Publicado: (2006)

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022)

Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study
por: Metcalfe, C, et al.
Publicado: (2009)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
por: Mills, Nicola, et al.
Publicado: (2011)

Addressing patient treatment preferences at trial recruitment
por: Mills, Nicola, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
por: Keeney, Edna, et al.
Publicado: (2022)

Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction
por: Ferraro, Simona, et al.
Publicado: (2021)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam
por: Wever, Elisabeth M., et al.
Publicado: (2010)

Prostate specific antigen /
Publicado: (2001)

Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients with Clinically Localized Prostate Cancer
por: Nowroozi, Mohammad Reza, et al.
Publicado: (2016)

The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density
por: Chen, Yue, et al.
Publicado: (2019)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer
por: Schmitz, Matthew D, et al.
Publicado: (2010)

Prostate-specific antigen testing accuracy in community practice
por: Hoffman, Richard M, et al.
Publicado: (2002)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
por: Ma, Chaoran, et al.
Publicado: (2023)

Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial
por: Biernacka, Kalina M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_se0s59qj103rl4l0n0256jajtt